PL1864667T3 - Zastosowanie proleków do podania do ciała szklistego oka - Google Patents

Zastosowanie proleków do podania do ciała szklistego oka

Info

Publication number
PL1864667T3
PL1864667T3 PL06290901T PL06290901T PL1864667T3 PL 1864667 T3 PL1864667 T3 PL 1864667T3 PL 06290901 T PL06290901 T PL 06290901T PL 06290901 T PL06290901 T PL 06290901T PL 1864667 T3 PL1864667 T3 PL 1864667T3
Authority
PL
Poland
Prior art keywords
prodrugs
intravitreal administration
intravitreal
administration
Prior art date
Application number
PL06290901T
Other languages
English (en)
Inventor
Laura Rabinovich-Guilatt
Grégory Lambert
Original Assignee
Santen Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Sas filed Critical Santen Sas
Publication of PL1864667T3 publication Critical patent/PL1864667T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06290901T 2006-06-01 2006-06-01 Zastosowanie proleków do podania do ciała szklistego oka PL1864667T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/444,349 US20070280902A1 (en) 2006-06-01 2006-06-01 Method for treating eye disease or conditions affecting the posterior segment of the eye
US11/444,337 US20070281914A1 (en) 2006-06-01 2006-06-01 Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye
EP06290902A EP1864668B1 (en) 2006-06-01 2006-06-01 Use of prodrugs for ocular intravitreous administration
EP06290901.5A EP1864667B1 (en) 2006-06-01 2006-06-01 Use of prodrugs for ocular intravitreous administration

Publications (1)

Publication Number Publication Date
PL1864667T3 true PL1864667T3 (pl) 2014-01-31

Family

ID=39712456

Family Applications (4)

Application Number Title Priority Date Filing Date
PL06290901T PL1864667T3 (pl) 2006-06-01 2006-06-01 Zastosowanie proleków do podania do ciała szklistego oka
PL10177375T PL2322183T3 (pl) 2006-06-01 2006-06-01 Wykorzystanie proleku do podawania doocznego, śródszklistkowego
PL06290902T PL1864668T3 (pl) 2006-06-01 2006-06-01 Wykorzystanie proleku do okulistycznego podawania śródszklistkowego
PL10177382T PL2319517T3 (pl) 2006-06-01 2006-06-01 Wykorzystanie proleku do podawania doocznego, śródszklistkowego

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL10177375T PL2322183T3 (pl) 2006-06-01 2006-06-01 Wykorzystanie proleku do podawania doocznego, śródszklistkowego
PL06290902T PL1864668T3 (pl) 2006-06-01 2006-06-01 Wykorzystanie proleku do okulistycznego podawania śródszklistkowego
PL10177382T PL2319517T3 (pl) 2006-06-01 2006-06-01 Wykorzystanie proleku do podawania doocznego, śródszklistkowego

Country Status (14)

Country Link
US (4) US20070280902A1 (pl)
EP (4) EP1864668B1 (pl)
JP (2) JP5284953B2 (pl)
KR (1) KR101408317B1 (pl)
CN (1) CN101553235B (pl)
AU (1) AU2007267079B2 (pl)
CA (1) CA2653902C (pl)
DK (2) DK2319517T3 (pl)
ES (1) ES2399976T3 (pl)
IL (1) IL195626A (pl)
PL (4) PL1864667T3 (pl)
PT (2) PT1864667E (pl)
SI (1) SI1864668T1 (pl)
WO (2) WO2007138113A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280902A1 (en) 2006-06-01 2007-12-06 Laura Rabinovich-Guilatt Method for treating eye disease or conditions affecting the posterior segment of the eye
PL2214646T3 (pl) 2007-10-05 2021-12-20 Wayne State University Dendrymery do przedłużonego uwalniania związków
JP2011505409A (ja) 2007-12-04 2011-02-24 ノバガリ ファーマ エスエー パルミチン酸デキサメタゾンのようなコルチコステロイドプロドラッグを含有する眼障害の治療用の組成物
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
UA116622C2 (uk) * 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
RU2660585C2 (ru) * 2012-02-10 2018-07-06 Тайвэн Липосом Компани, Лтд. Фармацевтическая композиция для уменьшения осложнений применения стероидных препаратов при лечении офтальмологических заболеваний
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
US11918657B2 (en) 2017-11-10 2024-03-05 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
CN111068071A (zh) * 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
PL3871662T3 (pl) * 2020-02-25 2023-11-20 Labomed Pharmaceutical Company S.A. Doustne roztwory zawierające octan fludrokortyzonu
CN116367824A (zh) 2020-09-16 2023-06-30 桑腾股份有限公司 用于玻璃体内施用的水包油乳剂
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2024167694A2 (en) * 2023-02-06 2024-08-15 Celularity Inc. Placental extracellular matrices for ocular delivery of ophthalmic therapeutic agents

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609726B2 (ja) 1980-05-15 1985-03-12 株式会社 ミドリ十字 ステロイド製剤
JPS5716818A (en) 1981-04-25 1982-01-28 Green Cross Corp:The Steroid fatty emulsion
AU531588B2 (en) 1981-08-17 1983-09-01 Yoshitomi Pharmaceutical Industries, Ltd. Emulsifying water-insoluble steroid
EP0244178A3 (en) * 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
WO1990001933A1 (en) * 1988-08-26 1990-03-08 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
JPH05132498A (ja) 1991-11-08 1993-05-28 Asahi Glass Co Ltd ステロイド誘導体およびその製剤
IL101241A (en) 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
CA2167818A1 (en) * 1993-08-02 1995-02-09 Robert George Whittaker Therapeutic compound - fatty acid conjugates
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
JP3410364B2 (ja) 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
DE69807281T2 (de) 1997-05-14 2003-04-17 Mitsubishi Chemical Corp., Tokio/Tokyo Difluprednat enthaltende Zusammensetzungen
IL121647A (en) * 1997-08-28 2001-07-24 Pharmateam Dev Ltd Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate
AU9281698A (en) 1997-10-01 1999-04-23 Wakamoto Pharmaceutical Co., Ltd. O/w emulsion compositions
JP2000212067A (ja) * 1999-01-19 2000-08-02 Towa Yakuhin Kk 薬物含有エマルジョン製剤
ATE468107T1 (de) 2001-11-01 2010-06-15 Yissum Res Dev Co Verfahren und zusammensetzung zur behandlung von trockenen augen
AU2003301129A1 (en) * 2002-12-20 2004-07-22 Control Delivery Systems, Inc. Steroid compositions for intraocular use
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
WO2005027882A1 (en) * 2003-09-22 2005-03-31 Bionetworks Gmbh Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
EP1611879B1 (en) * 2004-07-02 2009-08-12 Novagali Pharma SA Use of emulsions for intra- and periocular injection
WO2006017347A2 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
KR101341359B1 (ko) * 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
US20060094700A1 (en) * 2004-11-02 2006-05-04 Allergan, Inc. Heat sterilization of a steroid in the presence of phosphate
AU2005304035B2 (en) 2004-11-09 2010-07-22 Santen Sas Ophthalmic oil-in-water type emulsion with stable positive zeta potential
CN1905012A (zh) 2005-07-31 2007-01-31 新科实业有限公司 具有微驱动器的磁头折片组合及其磁盘驱动装置
US8109884B2 (en) 2005-09-23 2012-02-07 Kitchener Clark Wilson Dynamic metabolism monitoring system
US20070280902A1 (en) 2006-06-01 2007-12-06 Laura Rabinovich-Guilatt Method for treating eye disease or conditions affecting the posterior segment of the eye

Also Published As

Publication number Publication date
WO2007138113A1 (en) 2007-12-06
CN101553235A (zh) 2009-10-07
DK2319517T3 (da) 2013-12-09
WO2007138114A1 (en) 2007-12-06
US8227452B2 (en) 2012-07-24
CA2653902C (en) 2015-03-17
ES2399976T3 (es) 2013-04-04
DK1864668T3 (da) 2013-03-04
PT1864668E (pt) 2013-02-26
US20070281913A1 (en) 2007-12-06
EP2322183B1 (en) 2014-10-22
IL195626A0 (en) 2009-09-01
KR20090031373A (ko) 2009-03-25
SI1864668T1 (sl) 2013-04-30
US20070281914A1 (en) 2007-12-06
US20070280902A1 (en) 2007-12-06
PL2319517T3 (pl) 2014-01-31
JP2009538880A (ja) 2009-11-12
HK1110221A1 (en) 2008-07-11
EP1864667B1 (en) 2013-09-04
EP2319517A1 (en) 2011-05-11
PT1864667E (pt) 2013-11-18
EP1864668A1 (en) 2007-12-12
KR101408317B1 (ko) 2014-06-17
HK1110219A1 (en) 2008-07-11
JP2009538879A (ja) 2009-11-12
EP2322183A1 (en) 2011-05-18
EP1864668B1 (en) 2012-11-21
JP5284953B2 (ja) 2013-09-11
AU2007267079B2 (en) 2013-01-31
CA2653902A1 (en) 2007-12-06
JP5455624B2 (ja) 2014-03-26
US9192567B2 (en) 2015-11-24
AU2007267079A1 (en) 2007-12-06
IL195626A (en) 2017-05-29
PL1864668T3 (pl) 2013-04-30
US20070280995A1 (en) 2007-12-06
CN101553235B (zh) 2012-12-05
PL2322183T3 (pl) 2015-01-30
EP1864667A1 (en) 2007-12-12
EP2319517B1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
LTC2140867I2 (lt) Farmacinė kompozicija
BRPI0820381A2 (pt) Formulações farmacêuticas
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
EP3777939C0 (en) NASAL ROYALTY
EP2089308A4 (en) DONOR
DK2399580T3 (da) Farmaceutiske doseringsformer
PL3150586T3 (pl) Modulatory farmakokinetycznych właściwości środków terapeutycznych
BRPI0715712A2 (pt) Composição farmacêutica
DK1984009T3 (da) Farmaceutiske sammensætninger med forbedret stabilitet
BRPI0721651A2 (pt) Composição farmacêutica
EP2214542A4 (en) ELECTROMANUAL DISPENSER
BRPI0808293A2 (pt) "composições para administração nasal"
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0814188A2 (pt) Formulações
DK2144905T3 (da) Terapeutiske midler
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
PL1864667T3 (pl) Zastosowanie proleków do podania do ciała szklistego oka
DK2018158T3 (da) Ny racecadotril administrationsform
PT2209464E (pt) Composição farmacêutica antimalárica
EP2185112A4 (en) Stabilized therapeutic compositions and formulations
BRPI0820198A2 (pt) composições farmacêuticas
EP2007372A4 (en) Dialkyl-ABAGBEWIRKSTOFFE